Skip to content
Symbiotec Pharmalab logo

Symbiotec Pharmalab

SYMBIOTEC NSE
₹1,233.20 −29.80 (−2.36%)
P/E
99.45
View as Markdown
MCP
Close 4 Nov 2026 ₹1,233.20 +135.50 +12.3% since 1 Sep 2026
Start ₹1,097.70

Key Fundamentals

Microcap

Price-based figures as of · TTM

ROCE
13.00%
Debt to Equity
0.34
EPS (TTM)
₹12.40
Book Value
₹202.32
Market Cap
—
P/E (TTM)
99.45
P/B
6.10
ROE
11.70%
Dividend Yield
0.00%
EBITDA
₹241 Cr
52W High
₹1,309.90
52W Low
₹934.20
Day Range
₹1,226.10 – ₹1,273.60
Volume
6,31,594

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

Symbiotec Pharmalab peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Symbiotec Pharmalab (this company)
₹1,233.2099.45₹7,980 Cr6.100.00%11.70%13.00%₹670 Cr₹72 Cr
Median 8 companies₹1,587.7058.71₹1,25,337 Cr5.440.44%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Key Insights

Strengths

1
  • Company has reduced debt.

Weaknesses

3
  • Promoter holding is low: 33.3%
  • Company has a low return on equity of 12.9% over last 3 years.
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish4123
OscillatorsBearish261
Moving AveragesNeutral262

Key readings

RSI (14)
54.53
Neutral
MACD (12,26,9)
33.37
Bearish
SMA (50)
—
Neutral
SMA (200)
—
Neutral

As of

Analyst Rating

Based on 2 analysts
BUY100%

2 of 2 analysts rate Buy, 0 Hold, 0 Sell.

As of

BUY
2
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
5Y+6.54%
3Y+15.30%
1Y+15.56%

Net profit

Net profit growth by window
5Y−2.21%
3Y+68.48%
1Y+13.40%

Operating cash flow

Operating cash flow growth by window
5Y+0.11%
3Y+36.37%
1Y+272.34%

Operating margin· change in pp

Operating margin growth by window
5Y−3.31 pp
3Y+15.15 pp
1Y+0.51 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2021₹633 Cr
Mar 2022₹682 Cr
Mar 2023₹567 Cr
Mar 2024₹716 Cr
Mar 2025₹752 Cr
Mar 2026₹869 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2021₹123 Cr
Mar 2022₹78.00 Cr
Mar 2023₹23.00 Cr
Mar 2024₹100 Cr
Mar 2025₹97.00 Cr
Mar 2026₹110 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹283 Cr +17.5% vs FY26
Reported High Mean Low

Quarterly Results

₹ Cr
SYMBIOTEC quarterly results, ₹ crore
Particulars Jun 2025Mar 2026Jun 2026
Sales
203
245
218
Expenses
145
183
173
Operating Profit
58
62
45
OPM %
29%
25%
21%
Other Income
3
0
0
Interest
5
7
6
Depreciation
11
20
22
PBT
45
35
18
Tax %
33%
22%
20%
Net Profit
30
28
14
EPS (₹)
46.99
4.39
2.24

Profit & Loss

₹ Cr
SYMBIOTEC profit and loss, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
633
682
567
716
752
869
Expenses
438
550
497
544
549
630
Operating Profit
195
131
70
172
203
239
OPM %
31%
19%
12%
24%
27%
27%
Other Income
7
3
6
7
4
−6
Interest
7
3
8
8
17
26
Depreciation
22
26
29
39
43
53
PBT
173
105
39
132
147
153
Tax %
28%
27%
38%
23%
34%
28%
Net Profit
123
78
23
100
97
110
EPS (₹)
113
70.89
21.48
91.49
152
17.51
Div. Payout %
0%
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
SYMBIOTEC balance sheet, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
11
11
11
11
11
13
Reserves
510
588
611
704
804
1,137
Borrowings
47
65
218
247
544
391
Other Liabilities
200
152
151
326
220
240
Total Liabilities
768
815
990
1,289
1,580
1,781
Fixed Assets
261
280
299
448
438
1,120
CWIP
28
40
182
208
568
64
Investments
5
5
5
4
1
4
Other Assets
474
490
504
628
572
592
Total Assets
768
815
990
1,289
1,580
1,781

Cash Flow

₹ Cr
SYMBIOTEC cash flow, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
174
18
69
188
47
175
Investing
−96
−32
−220
−206
−307
−227
Financing
−79
15
146
22
278
36
Net Cash Flow
−1
1
−5
3
19
−16
Free Cash Flow
87
−55
−155
−22
−261
−50
CFO/OP
112
36
124
129
40
99

Ratios

SYMBIOTEC financial ratios, annual
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
68
77
72
64
85
83
Inventory Days
308
252
305
382
321
274
Days Payable
155
91
110
259
109
160
Cash Conversion Cycle
221
238
267
187
298
197
Working Capital Days
86
121
107
76
−3
−22
ROCE %
—
18%
6%
16%
14%
13%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Symbiotec Pharmalab insights

36 extracted metrics across FY21–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 33.28%
  • DIIs 33.17%
  • Others 21.96%
  • Public 7.81%
  • FIIs 3.79%

38.54% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Symbiotec Pharmalab

What does Symbiotec Pharmalab Ltd do?
Symbiotec is a research-driven, science- based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and Steroidal Hormone Active Pharmaceutical Ingredients (APIs).
Where is Symbiotec Pharmalab Ltd (SYMBIOTEC) listed?
Symbiotec Pharmalab Ltd trades as SYMBIOTEC on the NSE and under code 544889 on the BSE.
Which sector does Symbiotec Pharmalab Ltd belong to?
Symbiotec Pharmalab Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the PE ratio of Symbiotec Pharmalab Ltd?
Symbiotec Pharmalab Ltd trades at a PE ratio of 99.45 as of 4 Nov 2026, on earnings per share of ₹12.4, against a book value of ₹202.32 per share.
What is the 52-week high and low of Symbiotec Pharmalab Ltd?
Over the last 52 weeks Symbiotec Pharmalab Ltd has traded between ₹934.2 and ₹1,309.9 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Symbiotec Pharmalab Ltd?
Symbiotec Pharmalab Ltd reported a return on equity of 11.70%. Its debt-to-equity ratio is 0.34.

Company Information

Symbiotec is a research-driven, science- based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and Steroidal Hormone Active Pharmaceutical Ingredients (APIs). It has evolved from a Lab-Scale Steroid manufacturer into a fully integrated global platform.

Website symbiotec.com
Listed 1 Sep 2026
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SYMBIOTEC.md for Symbiotec Pharmalab Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month